Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9123183 | 0.94 | SPPL2A (0.49) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL9119065 | 0.88 | SPPL2A (0.55) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL9121380 | 0.88 | SPPL2A (0.48) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL14598706 | 0.87 | MLNR (0.47) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL9123764 | 0.87 | SPPL2A (0.56) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL5400367 | 0.87 | SPPL2A (0.40) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL8842365 | 0.86 | SPPL2A (0.49) | SPPL2A | |
| SCHEMBL9119249 | 0.86 | SPPL2A (0.49) | SPPL2A | |
| SCHEMBL2578965 | 0.85 | SPPL2A (0.49) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL7684686 | 0.84 | SPPL2A (0.52) | MLNRABCB11LMNACTSDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226932-B2 | Self-emulsifying drug delivery system | G.D. SEARLE LLC (US) | 2007-06-05 | — | — | US | disclosed |
| US-20040048934-A1 | Self-emulsifying drug delivery system | G.D. SEARLE & CO. | 2004-03-11 | — | — | US | disclosed |
| EP-0769936-A1 | SELF-EMULSIFYING DRUG DELIVERY SYSTEM | G.D. SEARLE & CO. (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996003113-A1 | SELF-EMULSIFYING DRUG DELIVERY SYSTEM | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048934-A1 | Self-emulsifying drug delivery system | LIPA, CEL, LSS | MLNR 802/4885ABCB11 12/4885LMNA 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.